🇺🇸 FDA
Patent

US 12202886

Neutralizing antibodies to GP120 and their use

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12202886 (Neutralizing antibodies to GP120 and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P31/18